Form D · Pharmaceuticals

AN2 Therapeutics, Inc.

Menlo Park, CA · CIK 0001880438

Offering snapshot reported Mar 25, 2026 · SEC filing

Reported sold
$40M
Offering amount: $40M
Investors reported
16
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 10, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 25, 2026Initial$39,999,989No comparison16SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2.4M
Finders' fees
$0
Form D file number
021-577698

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Leerink Partners LLC39011

Source: Form D, filed Mar 25, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kabeer Aziz Director
Sanjay Chanda Executive
Lucy Day Executive
Eric Easom Director, Executive
Joshua Eizen Executive
Margaret Fitz Patrick Director
Gilbert Lynn Marks Director
Patricia Martin Director
Rob Readnour Director
Melvin Spigelman Director
Stephanie Wong Director
Joseph S. Zakrzewski Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1300 El Camino Real, Suite 100
Menlo Park, CA, 94025
Phone: (650) 331-9090